Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Prothena

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson's Disease to be Presented at AAT-AD/PD

              Contact the Supplier

              Lead Product(s): Prasinezumab

              Therapeutic Area: Neurology

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 31, 2020

              Details:

              PASADENA is a two-part Phase 2 clinical study in patients with early Parkinson’s disease that is being conducted by Roche.

              NeuroSense Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              NeuroSense Receives Orphan Drug Designation for Amyotrophic

              Contact the Supplier

              Lead Product(s): Ciprofloxacin,Celecoxib

              Therapeutic Area: Neurology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 06, 2020

              Details:

              The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense's product for ALS patients.

              PharmaCompass__DigitalAd